TO: All County California Children’s Services Program Administrators, Medical Directors, and Integrated Systems of Care Division Staff

SUBJECT: California Children’s Services Program coverage of treatment for Central Precocious Puberty

I. PURPOSE

The purpose of this Numbered Letter (N.L.) is to define California Children’s Services Program (CCS) coverage of Gonadotropin-Releasing Hormone (GnRH) Agonists prescribed for the treatment of Central Precocious Puberty (CPP).

II. BACKGROUND

CPP is defined as the early maturation of the hypothalamic-pituitary-gonadal axis, leading to early onset of secondary sexual characteristics, before the age of 8 years in girls or 9 years in boys.

Causes include, but are not limited to, hypothalamic hamartoma, (optic) glioma and various other central nervous system tumors, suprasellar arachnoid cyst, hydrocephalus, neurofibromatosis type 1, tuberous sclerosis, septo-optic dysplasia (optic nerve hypoplasia), Chiari II malformations, myelomeningocele, granulomatous disease, cerebral palsy, and sequelae of other CCS-eligible conditions including central nervous system irradiation.

Evaluation of CPP is typically done when a female has breast development, accelerated height velocity, and crosses a growth chart percentile before age 8 years, or when a male has both testicular and penile enlargement before age 9 years. Additional diagnostic studies performed by CCS-paneled endocrinologists generally include basal (early-morning) levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol in girls, testosterone in boys, and, as

1 AAP Clinical Report, Evaluation and Referral of Children with Signs of Early Puberty, 2016
https://pediatrics.aappublications.org/content/pediatrics/137/1/e20153732.full.pdf
appropriate, GnRH stimulation test with basal and stimulated LH/FSH and estradiol in girls and testosterone in boys. Other studies may include measurement of adrenal steroids, pelvic and adrenal imaging, and rarely, contrast-enhanced head magnetic resonance imaging (MRI), or genetic testing.

Imaging studies may be ordered as part of the diagnostic process, including a contrast-enhanced brain MRI to rule out the presence of intracranial pathology (at the discretion of the pediatric endocrinologist) and/or a pelvic/adrenal ultrasound to rule out a steroid-secreting gonadal or adrenocortical tumor. Rarely, other imaging may be required to rule out a human chorionic gonadotropin-secreting tumor.

Treatment of CPP consists of a GnRH agonist which may be administered intramuscularly or by implant. See Attachment, “GnRH Agonist Treatment Options,” for specific drug information. The GnRH agonist provides continuous stimulation to the pituitary gonadatroph cells which leads to their desensitization, resulting in decreased production of LH and FSH and, in turn, decreased production of sex hormones (estradiol in girls and testosterone in boys).

III. POLICY

A. CCS clients are eligible to receive GnRH agonist therapy when all of the following criteria are met:

1. The client is between the ages of 2 and 10 years at the time of initial evaluation.

2. The client has been evaluated by a CCS-paneled endocrinologist at an endocrinology Special Care Center (SCC).

3. The diagnosis of CPP is made by the CCS-paneled endocrinologist at the SCC based on age of pubertal onset, rate of progression of pubertal changes, height velocity, and bone age (advanced more than two standard deviations above chronological age) or bone age acceleration (advancing more than one year per chronological year).

4. The diagnosis is confirmed when the client has one of the following laboratory findings:

---

2 Treatment of Central Precocious Puberty
a. Serum LH level exceeds prepubertal level (generally greater than 0.2 – 0.3 international units per litre (IU/L), depending on the assay used).

b. A positive GnRH stimulation test, defined by a peak LH level greater than or equal to 3.3 – 5 IU/L, depending on the assay, or a pubertal level of estradiol (girls) or testosterone (boys) detected (usually) 18 – 24 hours after the GnRH administration.

5. The GnRH agonist is prescribed by the CCS-paneled endocrinologist at an SCC.

B. When the conditions described in section III.A. are met, GnRH agonist treatment is medically necessary and shall be authorized as follows:

1. Initial authorization shall be for a standard GnRH agonist consistent with Pediatric Endocrine Society recommendations which are listed in the Attachment, “GnRH Agonist Treatment Options.”

2. Re-authorization of GnRH agonist therapy shall be every 12 months or until the CCS program eligibility end-date, as long as it is deemed efficacious demonstrated by plateauing or reversal of relevant pubertal changes on physical examination, persistent biochemical suppression of the hypothalamic-pituitary-gonadal axis, and continued predicted increase in adult height.

C. If the criteria described above are not met, but the requesting provider has clinical documentation and/or scientific evidence that may be relevant to the request, the provider may submit this additional documentation to the Integrated Systems of Care Division (ISCD) Medical Director or designee for consideration during the medical eligibility determination.

IV. POLICY ADMINISTRATION

A. For non-Whole Child Model (WCM) independent counties, requests for authorization of GnRH agonist treatment will be reviewed and authorized by county CCS Programs.

B. For dependent counties, requests for authorization of GnRH agonist treatment will be reviewed and authorized by the ISCD Special Populations Unit at CCS_Operations@dhcs.ca.gov, or to secure RightFax number, (916) 440-5768.

C. For WCM counties, requests for authorization of GnRH agonist treatment will be reviewed and authorized by the Managed Care Plan (MCP) and requests for
authorization should be directed to the appropriate authorization county-specific MCP authorization unit.

If you have any questions regarding this Numbered Letter, please contact the ISCD Medical Director or designee at ISCD-MedicalPolicy@dhcs.ca.gov.

Sincerely,

ORIGINAL SIGNED BY

Roy Schutzengel
Medical Director
Integrated Systems of Care Division

Attachment(s):
GnRH Agonist Treatment Options
<table>
<thead>
<tr>
<th>Drug</th>
<th>Route of Administration</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leuprolide acetate (Lupron Depot-Ped)</td>
<td>intramuscular</td>
<td>every 1-3 months</td>
</tr>
<tr>
<td>Histrelin acetate (Supprelin)</td>
<td>implant</td>
<td>every 12 months</td>
</tr>
<tr>
<td>Triptorelin pamoate (Triptodur)</td>
<td>intramuscular</td>
<td>every 6 months</td>
</tr>
</tbody>
</table>